Impact of right heart function and pulmonary venous Hypertension on CRT Response in patients with left ventricular dysfunction and dyssynchrony - Bivent

niversitätsklinikum Magdeburg0 个研究点目标入组 115 人开始时间: 2017年1月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients with heart failure symptoms lasting at least 6 weeks (according to the
•current guidelines for CRT treatment of chronic heart failure)
•2. At least 18 years of age
•3. Medical need for implants (implants based on the standard implant guidelines
•from the European Society of Cardiology (ESC))
•4. Left ventricular ejection fraction (LVEF) < 35% as assessed by the investigator
•5. NYHA functional status II, III or IV
•6. QRS duration > 130 ms
•7. Medical therapy, unless contraindicated, includes
•- ACE inhibitor or
•- AT1 blocker given for at least one month before enrolment,
•- Beta-blocker started at least 3 months before enrolment,
•- aldosterone antagonist
•Dosage of therapies mentioned above must be unchanged for at least one month.
•8. The patient must have given its written informed consent to participate in the
•study after receiving adequate previous information and prior to any study
•specific procedures.

•1. Life expectancy < 12 months
•2. Pregnancy (routine test before left and right heart catheter examination)
•3. Prior CRT
•4. Atrial arrhythmias
•5. Right bundle branch block
•6. QRS < 130 ms
•7. Heart failure requiring continuous intravenous therapy
•8. Patients with acute coronary syndromes or coronary revascularization within 4
•months before CRT

发起方

niversitätsklinikum Magdeburg